20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL) operates in the NASDAQ industry and is headquartered in San Diego, United States with about 106 employees. Its market capitalization is roughly $192 million. In the fiscal year ended 2025-12-31, ZNTL reported $0M in revenue and ($137M) in net income.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $67M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | $67M | ($1M) | ($1M) | ($1M) | $0M | $0M | $0M |
| Gross Margin % | — | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating Income (EBIT) | ($191M) | ($153M) | ($191M) | ($300M) | ($227M) | ($217M) | ($119M) | ($47M) | ($24M) |
| Operating Margin % | — | — | -283.6% | — | — | — | — | — | -169878.6% |
| Net Income | ($175M) | ($137M) | ($166M) | ($292M) | ($237M) | ($159M) | ($118M) | ($46M) | ($21M) |
| Net Margin % | — | — | -246.0% | — | — | — | — | — | -150478.6% |
| EBITDA | ($173M) | ($144M) | ($186M) | ($248M) | ($234M) | ($207M) | ($119M) | ($47M) | ($24M) |
| Earnings Per Share (EPS) | $-2.47 | $-1.91 | $-2.33 | $-4.47 | $-4.48 | $-3.72 | $-2.87 | $-1.27 | $-1.17 |
| Shares Outstanding (M) | 70M | 72M | 71M | 65M | 53M | 43M | 41M | 36M | 18M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $27M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | $0M | $27M | $0M |
| Gross Margin % | — | — | — | — | — | — | 100.0% | — |
| Operating Income (EBIT) | ($82M) | ($38M) | ($37M) | ($34M) | ($36M) | ($46M) | ($50M) | ($51M) |
| Operating Margin % | — | — | — | — | — | — | -185.5% | — |
| Net Income | ($78M) | ($35M) | ($35M) | ($27M) | ($27M) | ($48M) | ($47M) | ($40M) |
| Net Margin % | — | — | — | — | — | — | -176.7% | — |
| EBITDA | ($77M) | ($35M) | ($35M) | ($27M) | ($35M) | ($38M) | ($46M) | ($40M) |
| Earnings Per Share (EPS) | $-1.10 | $-0.50 | $-0.49 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 |
| Shares Outstanding (M) | 70M | 70M | 72M | 72M | 72M | 72M | 71M | 71M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($161M) | ($125M) | ($171M) | ($208M) | ($164M) | ($154M) | ($87M) | ($39M) | ($24M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $3M | $6M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($161M) | ($125M) | ($171M) | ($208M) | ($166M) | ($160M) | ($88M) | ($39M) | ($24M) |
| FCF Margin % | — | — | -253.7% | — | — | — | — | — | -174842.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($70M) | ($33M) | ($31M) | ($27M) | ($35M) | ($33M) | ($40M) | ($44M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($70M) | ($33M) | ($31M) | ($27M) | ($35M) | ($33M) | ($40M) | ($44M) |
| FCF Margin % | — | — | — | — | — | — | -147.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $215M | $289M | $430M | $562M | $553M | $472M | $366M | $88M | $41M |
| Cash & Cash Equivalents | $25M | $36M | $34M | $28M | $43M | $60M | $55M | $67M | $25M |
| Total Liabilities | $72M | $73M | $93M | $125M | $119M | $108M | $32M | $20M | $9M |
| Total Debt (Short + Long-Term) | $4M | $4M | $3M | $3M | $2M | $1M | $1M | $1M | $0M |
| Total Shareholders' Equity | $144M | $216M | $337M | $437M | $434M | $364M | $309M | $62M | $25M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZNTL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms